DUPIXENT SHOWED IMPROVEMENT IN LUNG FUNCTION1

Lung function improvement sustained through Week 52

Post‑bronchodilator FEV1

BOREAS Trial

Change in post‑bronchodilator FEV1 from baseline at Week 12 and Week 52 (ITT population; secondary endpoint)1,2

NOTUS Trial

Patients administered DUPIXENT + SOC saw numerical improvement in post‑bronchodilator FEV1 of 134 mL at Week 12 (n=470) and 127 mL at Week 52 (n=362), compared with 67 mL at Week 12 (n=465) and 59 mL at Week 52 (n=359) in patients receiving placebo + SOC (LSM change from baseline, ITT population)1

Post-bronchodilator lung function results are descriptive. Definitive conclusions cannot be made.

Pre‑bronchodilator FEV1

Significant improvements of similar magnitude were observed in change from baseline in pre-
bronchodilator FEV1 at Weeks 12 and 52 in subjects treated with DUPIXENT compared to placebo
across the BOREAS and NOTUS trials.1

Standard of care therapy was
triple inhaled therapy
(LAMA+LABA).1,4

BL, baseline; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; ITT, intention-to-treat; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LSM, least squares mean; SOC, standard of care.